Kymera Therapeutics, Inc. (NASDAQ:KYMR) Stock Has Consensus Price Target of $139.16

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) have been assigned an average rating of “Moderate Buy” from the twenty-seven analysts that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, twenty-three have issued a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $139.16.

Several equities analysts recently issued reports on the company. Barclays raised their price target on Kymera Therapeutics from $139.00 to $170.00 and gave the company an “overweight” rating in a report on Monday, November 2nd. Royal Bank Of Canada upped their target price on Kymera Therapeutics from $112.00 to $116.00 and gave the stock a “sector perform” rating in a research report on Friday, October 30th. Raymond James Financial reaffirmed an “outperform” rating on shares of Kymera Therapeutics in a report on Thursday, October 29th. Stifel Nicolaus raised their price target on Kymera Therapeutics from $132.00 to $152.00 and gave the company a “buy” rating in a research report on Tuesday, September 22nd. Finally, BTIG Research upped their price objective on Kymera Therapeutics from $134.00 to $139.00 and gave the stock a “buy” rating in a report on Thursday, October 29th.

Insider Buying and Selling at Kymera Therapeutics

In related news, CEO Nello Mainolfi sold 30,000 shares of the stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $113.80, for a total transaction of $3,414,000.00. Following the completion of the transaction, the chief executive officer directly owned 666,568 shares in the company, valued at approximately $75,855,438.40. This trade represents a 4.31% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Brian Adams sold 6,371 shares of the company’s stock in a transaction on Friday, September 4th. The stock was sold at an average price of $116.83, for a total transaction of $744,323.93. Following the transaction, the insider owned 50,254 shares in the company, valued at approximately $5,871,174.82. The trade was a 11.25% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 15.98% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. BlackRock Inc. acquired a new stake in shares of Kymera Therapeutics during the 2nd quarter valued at about $635,067,000. Merck & Co. Inc. purchased a new position in shares of Kymera Therapeutics during the second quarter valued at approximately $88,544,161. Bank of America Corp DE purchased a new position in Kymera Therapeutics in the second quarter valued at about $43,378,000. Braidwell LP grew its stake in Kymera Therapeutics by 12.0% in the second quarter. Braidwell LP now owns 378,163 shares of the company’s stock worth $43,364,000 after purchasing an additional 40,604 shares in the last quarter. Finally, Jennison Associates LLC boosted its stake in Kymera Therapeutics by 2.5% during the 1st quarter. Jennison Associates LLC now owns 508,999 shares of the company’s stock valued at $42,395,000 after purchasing an additional 12,334 shares during the period.

Kymera Therapeutics Stock Up 2.8%

Kymera Therapeutics stock opened at $131.73 on Wednesday. The firm has a market capitalization of $11.25 billion, a PE ratio of -36.39 and a beta of 2.04. The firm’s 50-day simple moving average is $115.68 and its 200 day simple moving average is $97.81. Kymera Therapeutics has a 52 week low of $56.75 and a 52 week high of $138.00.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings data on Thursday, October 29th. The company reported ($1.32) EPS for the quarter, missing analysts’ consensus estimates of ($1.26) by ($0.06). Kymera Therapeutics had a negative return on equity of 22.39% and a negative net margin of 285.33%. The business had revenue of $1.35 million during the quarter, compared to analyst estimates of $3.28 million. During the same period in the prior year, the firm earned ($0.94) EPS. The business’s revenue for the quarter was up .0% compared to the same quarter last year. On average, research analysts expect that Kymera Therapeutics will post -3.88 EPS for the current fiscal year.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical-stage biotechnology company focused on developing medicines that selectively eliminate disease-causing proteins through targeted protein degradation. Its approach is designed to use the cell’s natural protein-disposal system to remove proteins that may be difficult to address with conventional drug modalities.

The company’s research and development programs have targeted a range of disease areas, including immune-mediated and inflammatory conditions, cancer, and other serious illnesses.